Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- glofitamab
- Mavenclad (cladribine)
Interactions between your drugs
cladribine glofitamab
Applies to: Mavenclad (cladribine), glofitamab
Using cladribine together with glofitamab may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
cladribine food
Applies to: Mavenclad (cladribine)
Cladribine oral products can bind to other medications. This may increase your risk of experiencing side effects. To avoid or minimize the interaction, cladribine should be taken at least 3 hours before or after other medications. Talk to your doctor if you have any questions or concerns, or if you have trouble separating the dosing times. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Lunsumio
Lunsumio (mosunetuzumab-axgb) is used for the treatment of relapsed or refractory follicular ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.